Effects of Serenoa Repens, Selenium and Lycopene (Profluss®) on chronic inflammation associated with Benign Prostatic Hyperplasia: Results of "FLOG" (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre italian study

International Braz J Urol

Volumn 39, Issue 2, 2013, Pages 214-221

  Morgia, Giuseppe ^a   Cimino, Sebastiano ^a   Favilla, Vincenzo ^a   Russo, Giorgio Ivan ^a   Squadrito, Francesco ^e   Mucciardi, Giuseppe ^c   Masieri, Lorenzo ^b   Minutoli, Letteria ^d   Grosso, Giuseppe ^a   Castelli, Tommaso ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e NONE

Author keywords

Inflammation; Phytotherapy; Prostatic hyperplasia; Prostatitis; Serenoa

Indexed keywords

ANTIINFLAMMATORY AGENT; CAROTENOID; LYCOPENE; PLANT EXTRACT; PROSTATE SPECIFIC ANTIGEN; SELENIUM;

AGED; ARTICLE; B LYMPHOCYTE; BIOPSY; BLADDER OBSTRUCTION; BLOOD; CANCER GRADING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; ITALY; MACROPHAGE; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; SABAL; T LYMPHOCYTE; TREATMENT OUTCOME;

AGED; ANTI-INFLAMMATORY AGENTS; B-LYMPHOCYTES; BIOPSY; CAROTENOIDS; HUMANS; ITALY; MACROPHAGES; MALE; MIDDLE AGED; NEOPLASM GRADING; PLANT EXTRACTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATITIS; SELENIUM; SERENOA; T-LYMPHOCYTES; TREATMENT OUTCOME; URINARY BLADDER NECK OBSTRUCTION;

EID: 84881385982     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-5538.IBJU.2013.02.10     Document Type: Article

References (29)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984; 132: 474-9.
2. Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther. 2006; 28: 13-25.
3. Tang J, Yang J. Etiopathogenesis of benign prostatic hypeprlasia. Indian J Urol. 2009; 25: 312-7.
4. Roehrborn CG, Kaplan SA, Noble WD. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPE: Results from the MTOPS study. AUA Meeting 2005. J Urol, suppl., 2005; 173: 346, abstract 1277.
5. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008; 54: 1379-84.
6. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007; 51: 1202-16.
7. Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003; 43: 164-75.
8. Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol. 2007; 52: 964-72.
9. Comhaire F, Mahmoud A: Preventing diseases of the prostate in the elderly using hormones and nutriceuticals. Aging Male. 2004; 7: 155-69.
10. Suzuki M, Ito Y, Fujino T, Abe M, Umegaki K, Onoue S, et al.: Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol Sin. 2009; 30: 227-81.
11. Buck AC. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol. 2004; 172: 1792-9.
12. Diwadkar-Navsariwala V, Prins GS, Swanson SM, Birch LA, Ray VH, Hedayat S, et al. Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model. Proc Natl Acad Sci U S A. 2006; 103: 8179-84.
13. Schwarz S, Obermüller-Jevic UC, Hellmis E, Koch W, Jacobi G, Biesalski HK. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr. 2008; 138: 49-53.
14. Kandaş NO, Randolph C, Bosland MC. Differential effects of selenium on benign and malignant prostate epithelial cells: stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations. Nutr Cancer. 2009; 61: 251-64.
15. Wertz K, Siler U, Goralczyk R.: Lycopene: modes of action to promote prostate health. Arch Biochem Biophys. 2004; 430: 127-34.
16. Obermüller-Jevic UC, Olano-Martin E, Corbacho AM, Eiserich JP, van der Vliet A, Valacchi G, et al. Lycopene inhibits the growth of normal human prostate epithelial cells in vitro. J Nutr. 2003; 133: 3356-60.
17. Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int. 2001; 87: 797-805.
18. Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol. 1979; 121: 755-60.
19. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999; 84: 976-81.
20. Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, et al.: Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate. 2009; 69: 1774-80.
21. Mishra VC, Allen DJ, Nicolaou C, Sharif H, Hudd C, Karim OM, et al.: Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int. 2007; 100: 327-31.
22. Sebastiano C, Vincenzo F, Tommaso C, Giuseppe S, Marco R, Ivana C, et al.: Dietary patterns and prostatic diseases. Front Biosci (Elite Ed). 2012; 4: 195-204.
23. Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, López Farré A. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003; 44: 549-55.
24. Magri V, Trinchieri A, Perletti G, Marras E. Activity of Serenoa repens, lycopene and selenium on prostatic disease: evidences and hypotheses. Arch Ital Urol Androl. 2008; 80: 65-78.
25. Bonvissuto G, Minutoli L, Morgia G, Bitto A, Polito F, Irrera N, et al. Effect of Serenoa repens, lycopene, and selenium on proinflammatory phenotype activation: an in vitro and in vivo comparison study. Urology. 2011; 77: 248.e9-16.
26. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011; 60: 106-17.
27. Gui-Zhong L, Libo M, Guanglin H, Jianwei W. The correlation of extent and grade of inflammation with serum PSA levels in patients with IV prostatitis. Int Urol Nephrol. 2011; 43: 295-301.
28. Ozden C, Ozdal OL, Guzel O, Han O, Seckin S, Memis A. The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis. Int Urol Nephrol. 2007; 39: 859-63.
29. Kandirali E, Boran C, Serin E, Semercioz A, Metin A. Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology. 2007; 70: 743-7.